Erlotinib-induced breast cancer regression

Annals of Pharmacotherapy

Volumn 40, Issue 11, 2006, Pages 2043-2047

  Catania, Chiara ^a   De Pas, Tommaso Martino ^a   Pelosi, Giuseppe ^a,b   Manzotti, Michela ^a   Adamoli, Laura ^a   Nolè, Franco ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; EGFR inhibitors; Erlotinib

Indexed keywords

CA 15-3 ANTIGEN; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; KI 67 ANTIGEN; METHOTREXATE; MORPHINE; NAVELBINE; PACLITAXEL; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; IMAGE ANALYSIS; INVASIVE DUCTAL BREAST CARCINOMA; LUNG METASTASIS; LYMPHANGITIS; MALIGNANT CUTANEOUS LYMPHANGITIS; PAIN; PERITONEUM METASTASIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN ULCER; SUBCUTANEOUS MASTECTOMY; SYMPTOM;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; REMISSION INDUCTION;

EID: 33750986839     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H252     Document Type: Article

References (16)

1. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
2. Fox SB, Harris AL. The epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 1997;2:131-41.
3. Klijn JG, Berns PM, Schmitz PI, et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992;13:3-17.
4. Nicholson RI, Hutcheson IR, Harper ME, et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001;8:175-82.
5. Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002;71:67-75.
6. Umekita Y, Ohi Y, Sagara Y, et al. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer 2000;89:484-7.
7. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999;53:167-76.
8. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005;23:5323-33.
9. Lewis S, Locker A, Todd JH, et al. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 1990;43:385-9.
10. Agrawal A, Gutteridge E, Gee JMW, Nicholson RI, Robertson JFR. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 2005;12(suppl 1):S135-44.
11. Robertson JFR, Gutteridge E, Cheung KL, et al. Gefitinib is active in acquired tamoxifen-resistant oestrogen receptor positive and oestrogen receptor negative breast cancer: results from a phase II study (abstract 23). In: Proceedings of the American Society of Clinical Oncology, 39th Annual Meeting, Chicago, IL, May 31-June 3, 2003.
12. Albain K, Elledge R, Gradishar WJ, et al. Open label phase II multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer. Breast Cancer Res Treat 2002;76(suppl A1):A20.
13. von Minckwitz G, Jonat W, Fasching P, et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 2005;89:165-72.
14. Tan AR, Yang X, Hewitt SM, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004;22:3080-90.
15. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
16. Tsao MS, Sakurada A, Cutz J, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.